Bayer Ag Stock Beta
| BAYZF Stock | USD 20.44 0.29 1.44% |
Bayer AG fundamentals help investors to digest information that contributes to Bayer AG's financial success or failures. It also enables traders to predict the movement of Bayer Pink Sheet. The fundamental analysis module provides a way to measure Bayer AG's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bayer AG pink sheet.
Bayer |
Bayer AG Company Beta Analysis
Bayer AG's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Bayer AG Beta | 1.17 |
Most of Bayer AG's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bayer AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Bayer AG has a Beta of 1.169. This is 35.93% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The beta for all United States stocks is notably lower than that of the firm.
Bayer Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bayer AG's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Bayer AG could also be used in its relative valuation, which is a method of valuing Bayer AG by comparing valuation metrics of similar companies.Bayer AG is currently under evaluation in beta category among its peers.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Bayer AG will likely underperform.
Bayer Fundamentals
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0576 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 87.41 B | |||
| Shares Outstanding | 982.42 M | |||
| Shares Owned By Institutions | 47.11 % | |||
| Price To Earning | 321.83 X | |||
| Price To Book | 1.36 X | |||
| Price To Sales | 1.06 X | |||
| Revenue | 44.08 B | |||
| Gross Profit | 27.04 B | |||
| EBITDA | 6.45 B | |||
| Net Income | 1000 M | |||
| Cash And Equivalents | 8.19 B | |||
| Cash Per Share | 8.34 X | |||
| Total Debt | 35.55 B | |||
| Debt To Equity | 1.17 % | |||
| Current Ratio | 1.18 X | |||
| Book Value Per Share | 42.01 X | |||
| Cash Flow From Operations | 5.09 B | |||
| Earnings Per Share | 5.13 X | |||
| Price To Earnings To Growth | 1.31 X | |||
| Number Of Employees | 102.3 K | |||
| Beta | 1.17 | |||
| Market Capitalization | 64.24 B | |||
| Total Asset | 120.24 B | |||
| Working Capital | 8.49 B | |||
| Current Asset | 25.17 B | |||
| Current Liabilities | 16.68 B | |||
| Z Score | 0.6 | |||
| Annual Yield | 0.03 % | |||
| Five Year Return | 4.07 % | |||
| Net Asset | 120.24 B | |||
| Last Dividend Paid | 2.0 |
About Bayer AG Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bayer AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bayer AG using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bayer AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Bayer Pink Sheet
Bayer AG financial ratios help investors to determine whether Bayer Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bayer with respect to the benefits of owning Bayer AG security.